OCULAR MECHANISMS OF REJECTION OF CORNEAL ENDOTHELIUM
角膜内皮排斥的眼部机制
基本信息
- 批准号:3263050
- 负责人:
- 金额:$ 9.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1986
- 资助国家:美国
- 起止时间:1986-08-01 至 1992-07-31
- 项目状态:已结题
- 来源:
- 关键词:T lymphocyte alpha fetoprotein antibody dependent killer cell cell mediated lymphocytolysis test cornea corneal endothelium cyclosporines disease /disorder model eye transplantation glucocorticoids helper T lymphocyte histocompatibility histocompatibility antigens homologous transplantation human subject immunochemistry inflammation interferons keratoplasty laboratory mouse laboratory rabbit leukocyte activation /transformation mixed lymphocyte reaction test prostaglandin E
项目摘要
Immunological rejection is the leading cause of late failure of corneal
grafts, most commonly in high-risk recipients with already vascularized
corneas or with chronic inflammatory disease of the anterior segment. The
endothelium is the principally affected tissue in at least half of clinical
corneal allograft rejections. The expression of Class II alloantigens
(HLA-DP, -DQ, -DR in humans; Ia in animals) may be induced by gamma
interferon on a variety of target cells including corneal endothelium
(Donnelly et al, Invest Ophth Vis Sci 26:575; Young et al., Invest Ophth
Vis Sci 26:570; 1985). Immunogenic inflammation in the anterior segment of
the eye is accompanied by the local production of Ia-inducing
lymphokines,and the expression of Ia antigens on corneal endothelium
(Donnelly and Prendergast, Cell Immunol 86:557, 1984; Donnelly et al., op.
cit.). Class II alloantigen expression on a grafted cornea could increase
the potential of the endothelium to excite local immune responses, and/or
its susceptibility to lysis by immune effectors. In this event, the
probability of success of high-risk clinical corneal grafts would be
improved by matching for Class II alloantigens, or by inhibiting the
induction of these antigens on the donor cornea.
The present studies will define in detail the time course of local
Ia-inducing lymphokine production and endothelial Ia expression during the
rejection of orthotopic corneal allografts in a rabbit model. The ability
of Ia-bearing endothelial cells to initiate the afferent limb of the immune
response by inducing helper T lymphocyte proliferation, inducing the
formation of allospecific cytolytic T lymphocytes (CTL), and processing and
presenting alloantigens to helper T cells and CTL, will be determined in an
inbred mouse in vitro model. The susceptibility of Ia-bearing corneal
endothelium to lysis by CTL, representing the efferent limb of the immune
response, also will be determined in an in vitro mouse model. The findings
in animal models will be correlated with human corneal allograft rejection
by immunohistochemical staining of DR and DP/DQ antigens in rejected
corneas and in corneas from chronically inflamed eyes.
免疫排斥反应是角膜移植术后晚期失败的主要原因
移植物,最常见于已经血管化的高危受者
角膜或患有前段慢性炎症性疾病。 的
在至少一半的临床疾病中,内皮是主要受影响的组织。
角膜移植排斥反应 II类同种异体抗原的表达
(人类HLA-DP,-DQ,-DR;动物Ia)可由γ-
干扰素作用于包括角膜内皮在内的多种靶细胞
(Donnelly等人,Invest Ophth维斯科学26:575; Young等人,投资Ophth
维斯科学26:570; 1985)。 眼前节免疫原性炎症
眼内伴有局部产生的Ia诱导
角膜内皮细胞Ia抗原的表达
(Donnelly和Prendergast,Cell Immunol 86:557,1984; Donnelly等人,op.
同前)。 移植角膜上的II类同种异体抗原表达可以增加
内皮激发局部免疫应答的潜力,和/或
它对免疫效应物溶解的敏感性。 在这一事件中,
高风险临床角膜移植的成功概率为
通过匹配II类同种异体抗原或通过抑制
在供体角膜上诱导这些抗原。
目前的研究将详细定义当地的时间进程,
Ia诱导的淋巴因子产生和内皮细胞Ia表达
兔角膜原位移植排斥反应的研究 的能力
的Ia-轴承内皮细胞启动传入肢体的免疫
通过诱导辅助性T淋巴细胞增殖,诱导
同种特异性溶细胞性T淋巴细胞(CTL)的形成,以及加工和
将同种抗原呈递给辅助性T细胞和CTL,将在一项研究中确定。
近交系小鼠体外模型。 载Ia角膜的易感性
内皮细胞被CTL裂解,代表免疫球蛋白的传出支。
反应,也将在体外小鼠模型中确定。 这些发现
在动物模型中,将与人角膜移植排斥反应相关
免疫组化法检测排斥反应中DR和DP/DQ抗原
角膜和慢性发炎眼睛的角膜。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN ROCKEY其他文献
JOHN ROCKEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN ROCKEY', 18)}}的其他基金
OCULAR MECHANISMS OF REJECTION OF CORNEAL ENDOTHELIUM
角膜内皮排斥的眼部机制
- 批准号:
3263049 - 财政年份:1986
- 资助金额:
$ 9.95万 - 项目类别:
OCULAR MECHANISMS OF INFLAMMATORY DISEASES OF THE EYE
眼部炎症性疾病的眼部机制
- 批准号:
3258462 - 财政年份:1982
- 资助金额:
$ 9.95万 - 项目类别:
OCULAR MECHANISMS OF INFLAMMATORY DISEASES OF THE EYE
眼部炎症性疾病的眼部机制
- 批准号:
3258461 - 财政年份:1982
- 资助金额:
$ 9.95万 - 项目类别:
OCULAR MECHANISMS OF INFLAMMATORY DISEASES OF THE EYE
眼部炎症性疾病的眼部机制
- 批准号:
3258456 - 财政年份:1982
- 资助金额:
$ 9.95万 - 项目类别:
OCULAR MECHANISMS OF INFLAMMATORY DISEASES OF THE EYE
眼部炎症性疾病的眼部机制
- 批准号:
3258460 - 财政年份:1982
- 资助金额:
$ 9.95万 - 项目类别:
OCULAR MECHANISMS OF INFLAMMATORY DISEASES OF THE EYE
眼部炎症性疾病的眼部机制
- 批准号:
3258463 - 财政年份:1982
- 资助金额:
$ 9.95万 - 项目类别:
相似海外基金
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines
改造甲胎蛋白和磷脂酰肌醇蛋白聚糖 3 以开发肝癌 (HCC) 疫苗
- 批准号:
8693488 - 财政年份:2014
- 资助金额:
$ 9.95万 - 项目类别:
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines
改造甲胎蛋白和磷脂酰肌醇蛋白聚糖 3 以开发肝癌 (HCC) 疫苗
- 批准号:
9231438 - 财政年份:2014
- 资助金额:
$ 9.95万 - 项目类别:
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines
改造甲胎蛋白和磷脂酰肌醇蛋白聚糖 3 以开发肝癌 (HCC) 疫苗
- 批准号:
8827287 - 财政年份:2014
- 资助金额:
$ 9.95万 - 项目类别:
Suppression of alpha-fetoprotein related hepatocellular proliferation and hepatocellular carcinogenesis in nonalcoholic steatohepatitis
抑制非酒精性脂肪性肝炎中甲胎蛋白相关的肝细胞增殖和肝细胞癌变
- 批准号:
24590981 - 财政年份:2012
- 资助金额:
$ 9.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Induktion einer spezifischen Immunantwort gegen alpha-Fetoprotein mittels AFP-Adenovirus-transfizierter dendritischer Zellen in vitro und in vivo zur Therapie des HCC
使用 AFP 腺病毒转染的树突状细胞在体外和体内诱导针对甲胎蛋白的特异性免疫应答以治疗 HCC
- 批准号:
5417539 - 财政年份:2004
- 资助金额:
$ 9.95万 - 项目类别:
Research Grants
Analysis of alpha-fetoprotein immune responses in patient with hepatocellular carcinoma
肝细胞癌患者甲胎蛋白免疫反应分析
- 批准号:
5378445 - 财政年份:2002
- 资助金额:
$ 9.95万 - 项目类别:
Research Grants
Alpha-Fetoprotein spezifische Immuntherapie des hepatozellulären Karzinoms (C 5)
肝细胞癌(C 5)的甲胎蛋白特异性免疫治疗
- 批准号:
5205850 - 财政年份:2000
- 资助金额:
$ 9.95万 - 项目类别:
Collaborative Research Centres
ALPHA FETOPROTEIN ENHANCERS/LIVER SPECIFIC TRANSCRIPTION
α胎蛋白增强剂/肝脏特异性转录
- 批准号:
2487123 - 财政年份:1998
- 资助金额:
$ 9.95万 - 项目类别:
STEROID HORMONES, ALPHA FETOPROTEIN AND BREAST CANCER
类固醇激素、α 胎蛋白和乳腺癌
- 批准号:
2437805 - 财政年份:1997
- 资助金额:
$ 9.95万 - 项目类别:
IN VITRO RECONSTITUTION OF ALPHA FETOPROTEIN REGULATION
α 胎蛋白调节的体外重建
- 批准号:
6386241 - 财政年份:1997
- 资助金额:
$ 9.95万 - 项目类别: